Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service CSF shunts cases in Minnesota: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 10% on average (47 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 2 | 140 | 49% |
| 2020 | 2 | 146 | 52% |
| 2021 | 4 | 180 | 56% |
| 2022 | 1 | 181 | 59% |
| 2023 | 1 | 171 | 62% |
| 2024 | 3 | 172 | 64% |
| 2025 from claims | – | 206 166–242 | 65% |
| 2026 forecast | – | 244 191–306 | 61% |
| 2027 forecast | – | 264 196–349 | 61% |
| 2028 forecast | – | 286 203–395 | 61% |
| 2029 forecast | – | 311 211–445 | 60% |
| 2030 forecast | – | 337 221–500 | 60% |
Ventriculoperitoneal shunt placement and revision, including normal-pressure hydrocephalus. Professional codes (what the surgeon bills): CPT 62223, 62230.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Minnesota; 2 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% inpatient hospital.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Ohio | 5 | 266−5.3%/yr | −5.3%/yr | 0.2 | 0% | 270 in 2030+0.2%/yr |
| Illinois | 1 | 244−3.5%/yr | −3.5%/yr | 0.2 | 0% | 310 in 2030+4.3%/yr |
| Missouri | 0 | 137−5.5%/yr | −5.5%/yr | 0.2 | 0% | 180 in 2030+4.6%/yr |
| Michigan | 0 | 130−12%/yr | −12%/yr | 0.2 | 0% | 290 in 2030+14%/yr |
| Wisconsin | 0 | 105+1.8%/yr | +1.8%/yr | 0.2 | 0% | 120 in 2030+2.7%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| DBS & VNS | 3 | 324−2.1%/yr | −2.1%/yr | 0.72.2× | 0% | 460 in 2030+6.1%/yr |
| Aneurysm & intracranial embolization | 8 | 304+10%/yr | +10%/yr | 0.71.7× | 0% | 720 in 2030+16%/yr |
| Stroke thrombectomy | 6 | 178−8.1%/yr | −8.1%/yr | 0.41.0× | 0% | 280 in 2030+7.8%/yr |
CSF shunts in every state, and its device makers · Every procedure market in Minnesota · Every state · Compare with Ohio
Johnson & Johnson MedTech leads with 97% of company spending on these surgeons in 2025, +13 pts on 2024.
In 2025, 5 companies reported engagement with Minnesota’s surgeons worth $57K in consulting, speaking, meals and travel tied to these products, about $19K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 4 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.